Adjuvant immunotherapy with high-dose ipilimumab has led to improvements in overall survival, whereas therapy with nivolumab and pembrolizumab has improved relapse-free survival with greater safety. Furthermore, adjuvant-targeted therapy with dabrafenib and trametinib has improved survival outcomes in BRAFV...
Current Oncology Reports (2024) 26:735–743 https://doi.org/10.1007/s11912-024-01539-0 REVIEW Axillary Management: How Much Is Too Much? Nicci Owusu‑Brackett1 · Benjin Facer2 · Dionisia Quiroga3 · Ashley Pariser3 · Michael Grimm4 · Sasha Beyer2 · ...
Normal tissues usu- ally express much lower level of the targets compared to tumor tissues [34]. Selection of IgG subclasses for targets expressed in immune cells Selection of IgG subclasses for immune cell targets is more complicated because some targets act to regulate immune function by ...
While surgery remains a cornerstone of skin cancer treatment, advancements in surgical techniques are improving outcomes.Mohs surgery, for example, allows for the precise removal of cancerous tissue while keeping as much healthy tissue as possible. This technique is especially effective for non-melanoma...
(3) how much do pathologists trust and accept AI? and (4) what is the best practical scoring scheme for PD-L1 expression in breast cancer? What is AI’s role in PD-L1 expression assessment? Human pathologists are not good at precisely evaluating ratios, especially when hundreds of cells ...
Pembrolizumab (Keytruda) This medicine is a checkpoint inhibitor used for high-risk, early-stage, triple-negative breast cancer (TNBC). It's done along with chemotherapy. It can also be given to treat metastatic TNBC when the tumor makes PD-L1 protein. ...
New therapies that arm the immune system to fight cancer, such as Keytruda (pembrolizumab) and Yervoy (ipilimumab), have offered patients with advanced melanoma real hope of effective treatment.
The pCR rate is the quite popular surrogate of survival outcomes of neoadjuvant therapy because it requires a much shorter time of follow-up. A literature-based meta-analysis of randomized clinical trials conducted by Petrelli et al. demonstrated that both the pCR rate and 3-year DFS were not...
Lenvatinib + pembrolizumab Nivolumab + ipilimumab Single-agent TKI OtherVote DISCUSSION QUESTIONS To what extent is risk status a deciding factor in your first-line treatment decision making? What drives your selection of first-line therapy for favorable-risk, metastatic ccRCC? Thai H. Ho,...
There is a clear and urgent necessity to lower cancer drug prices to keep lifesaving drugs available and affordable for patients. As one patient advocate recently put it: “Innovation is meaningless if nobody can afford it.” Lack of Effective Solutions Much has been written about the reasons ...